Trasplante renal en pacientes con infección por el virus de la inmunodeficiencia humana: revisión de la literatura
DOI:
https://doi.org/10.17533/udea.iatreia.144Palabras clave:
síndrome de inmunodeficiencia adquirida, VIH, trasplante de riñón, insuficiencia renal crónicaResumen
El trasplante renal es el tratamiento de elección en la enfermedad renal crónica terminal porque mejora la calidad de vida y la supervivencia de los pacientes al compararlo con la diálisis. Sin embargo, para mantener un injerto funcional y evitar el rechazo es necesario el uso de inmunosupresión potente durante toda la vida del injerto, lo cual puede tener como complicaciones una mayor susceptibilidad a presentar infecciones, desarrollo de cáncer, alteraciones metabólicas y problemas cardiovasculares. Los pacientes infectados con el virus de la inmunodeficiencia humana tienen alto riesgo de desarrollar enfermedad renal crónica terminal por múltiples causas. En el siglo pasado, el trasplante renal se consideraba contraindicado para estos pacientes. No obstante, hoy en día el trasplante renal se considera una opción terapéutica para pacientes adecuadamente seleccionados y con protocolos de manejo bien establecidos. Reportándose supervivencia reportadas del injerto y del paciente a tres años de 88,2 % y 82,6 % respectivamente. Este artículo de revisión tiene como objetivo revisar la experiencia mundial existente en el manejo de los pacientes trasplantados renal con infección por VIH.
Descargas
Citas
(1) Wilson EM, Sereti I. Immune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs. Immunol Rev. 2013;254(1):343-54. DOI 10.1111/imr.12064.
(2) Stock PG, Barin B, Murphy B, Hanto D, Diego JM, Light J, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010;363(21):2004-14. DOI 10.1056/NEJMoa1001197.
(3) Gutierrez E, Morales E, Gutierrez Martinez E, Manzanares MJ, Rosello G, Merida E, et al. Glomerulopathies associated to HIV infection: a Spanish perspective. Nefrologia. 2007;27(4):439-47.
(4) García P, Munévar M, Benavides C, Contreras K. First kidney transplant in Colombia in a patient with HIV infection. Acta Med Colomb. 2015;40:162-5.
(5) González-Gámez M, Carrillo-Pérez DL, Carrillo-Maravilla E. Enfermedad renal asociada a infección por virus de inmunodeficiencia humana (VIH). Revista Médica. 2015;5(3):126-33.
(6) Higuita LM, Nieto-Ríos JF, Daguer-Gonzalez S, Ocampo-Kohn C, Aristizabal-Alzate A, Velez-Echeverri C, et al. Tuberculosis in renal transplant patients: the experience of a single center in Medellín-Colombia, 2005-2013. J Bras Nefrol. 2014 Oct-Dec;36(4):512-8. DOI 10.5935/0101-2800.20140073.
(7) Nieto-Ríos JF, Serna-Higuita LM, Guzman-Luna CE, Ocampo-Kohn C, Aristizabal-Alzate A, Ramírez I, et al. Histoplasmosis in renal transplant patients in an endemic area at a reference hospital in Medellin, Colombia. Transplant Proc. 2014 Nov;46(9):3004-9. DOI 10.1016/j.transproceed.2014.06.060.
(8) Palau L, Menez S, Rodriguez-Sanchez J, Novick T, Delsante M, McMahon BA, et al. HIV-associated nephropathy: links, risks and management. HIV AIDS (Auckl). 2018 May 25;10:73-81. DOI 10.2147/HIV.S141978.
(9) Mallipattu SK, Wyatt CM, He JC. The New Epidemiology of HIV-Related Kidney Disease. J AIDS Clin Res. 2012;Suppl 4:001. DOI 10.4172/2155-6113.S4-001.
(10) Alfano G, Cappelli G, Fontana F, Di Lullo L, Di Iorio B, Bellasi A, et al. Kidney Disease in HIV Infection. J Clin Med. 2019;8(8). DOI 10.3390/jcm8081254.
(11) Cohen SD, Kopp JB, Kimmel PL. Kidney Diseases Associated with Human Immunodeficiency Virus Infection. N Engl J Med. 2017;377(24):2363-74. DOI 10.1056/NEJMra1508467.
(12) Romagnani P, Remuzzi G, Glassock R, Levin A, Jager KJ, Tonelli M, et al. Chronic kidney disease. Nat Rev Dis Primers. 2017;3:17088. DOI 10.1038/nrdp.2017.88.
(13) Abraham AG, Althoff KN, Jing Y, Estrella MM, Kitahata MM, Wester CW, et al. End-stage renal disease among HIV-infected adults in North America. Clin Infect Dis. 2015;60(6):941-9. DOI 10.1093/cid/ciu919.
(14) Saracho R, Martin Escobar E, Comas Farnes J, Arcos E, Mazuecos Blanca A, Gentil Govantes MA, et al. Clinical evolution of chronic renal patients with HIV infection in replacement therapy. Nefrologia. 2015;35(5):457-64. DOI 10.1016/j.nefro.2015.06.027.
(15) Trullas JC, Cofan F, Barril G, Martinez-Castelao A, Jofre R, Rivera M, et al. Outcome and prognostic factors in HIV-1-infected patients on dialysis in the cART era: a GESIDA/SEN cohort study. J Acquir Immune Defic Syndr. 2011;57(4):276-83. DOI 10.1097/QAI.0b013e318221fbda.
(16) Locke JE, Mehta S, Sawinski D, Gustafson S, Shelton BA, Reed RD, et al. Access to Kidney Transplantation among HIV-Infected Waitlist Candidates. Clin J Am Soc Nephrol. 2017;12(3):467-75. DOI 10.2215/CJN.07460716.
(17) Tourret J, Guiguet M, Lassalle M, Grabar S, Lievre L, Isnard-Bagnis C, et al. Access to the waiting list and to kidney transplantation for people living with HIV: A national registry study. Am J Transplant. 2019;19(12):3345-55. DOI 10.1111/ajt.15500.
(18) Sawinski D, Wyatt CM, Casagrande L, Myoung P, Bijan I, Akalin E, et al. Factors associated with failure to list HIV-positive kidney transplant candidates. Am J Transplant. 2009;9(6):1467-71. DOI 10.1111/j.1600-6143.2009.02637.x.
(199 Lee DH, Boyle SM, Malat GE, Kern C, Milrod C, DeBellis S, et al. Barriers to listing for HIV-infected patients being evaluated for kidney transplantation. Transpl Infect Dis. 2017;19(6). DOI 10.1111/tid.12777.
(20) Locke JE, Gustafson S, Mehta S, Reed RD, Shelton B, MacLennan PA, et al. Survival Benefit of Kidney Transplantation in HIV-infected Patients. Ann Surg. 2017;265(3):604-8. DOI 10.1097/SLA.0000000000001761.
(21) Blumberg EA, Rogers CC, American Society of Transplantation Infectious Diseases Community of P. Solid organ transplantation in the HIV-infected patient: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13499. DOI 10.1111/ctr.13499.
(22) Blumberg EA, Rogers CC, Practice ASTIDCo. Human immunodeficiency virus in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:169-78. DOI 10.1111/ajt.12109.
(23) Tan-Tam CC, Frassetto LA, Stock PG. Liver and kidney transplantation in HIV-infected patients. AIDS Rev. 2009;11(4):190-204.
(24) Swanepoel CR, Atta MG, D’Agati VD, Estrella MM, Fogo AB, Naicker S, et al. Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2018;93(3):545-59. DOI 10.1016/j.kint.2017.11.007.
(25) Kucirka LM, Durand CM, Bae S, Avery RK, Locke JE, Orandi BJ, et al. Induction Immunosuppression and Clinical Outcomes in Kidney Transplant Recipients Infected with Human Immunodeficiency Virus. Am J Transplant. 2016;16(8):2368-76. DOI 10.1111/ajt.13840.
(26) Locke JE, Mehta S, Reed RD, MacLennan P, Massie A, Nellore A, et al. A National Study of Outcomes among HIV-Infected Kidney Transplant Recipients. J Am Soc Nephrol. 2015;26(9):2222-9. DOI 10.1681/ASN.2014070726.
(27) Carter JT, Melcher ML, Carlson LL, Roland ME, Stock PG. Thymoglobulin-associated Cd4+ T-cell depletion and infection risk in HIV-infected renal transplant recipients. Am J Transplant. 2006;6(4):753-60. DOI 10.1111/j.1600-6143.2006.01238.x.
(28) Trullas JC, Cofan F, Cocchi S, Cervera C, Linares L, Aguero F, et al. Effect of thymoglobulin induction on HIV-infected renal transplant recipients: differences between HIV-positive and HIV-negative patients. AIDS Res Hum Retroviruses. 2007;23(10):1161-5. DOI 10.1089/aid.2007.0015.
(29) Trullas JC, Cofan F, Tuset M, Ricart MJ, Brunet M, Cervera C, et al. Renal transplantation in HIV-infected patients: 2010 update. Kidney Int. 2011;79(8):825-42. DOI 10.1038/ki.2010.545.
(30) Locke JE, James NT, Mannon RB, Mehta SG, Pappas PG, Baddley JW, et al. Immunosuppression regimen and the risk of acute rejection in HIV-infected kidney transplant recipients. Transplantation. 2014;97(4):446-50. DOI 10.1097/01.TP.0000436905.54640.8c.
(31) Shaffer AA, Durand CM. Solid Organ Transplantation for HIV-Infected Individuals. Curr Treat Options Infect Dis. 2018;10(1):107-20. DOI 10.1007/s40506-018-0144-1.
(32) Nashar K, Sureshkumar KK. Update on kidney transplantation in human immunodeficiency virus infected recipients. World J Nephrol. 2016;5(4):300-7. DOI 10.5527/wjn.v5.i4.300.
(33) Norman SP, Kommareddi M, Kaul DR. Update on kidney transplantation in HIV-infected recipients. AIDS Rev. 2012;14(3):195-207.
(34) Harbell J, Terrault NA, Stock P. Solid organ transplants in HIV-infected patients. Curr HIV/AIDS Rep. 2013;10(3):217-25. DOI 10.1007/s11904-013-0170-z.
(35) Gathogo E, Harber M, Bhagani S, Levy J, Jones R, Hilton R, et al. Impact of Tacrolimus Compared with Cyclosporin on the Incidence of Acute Allograft Rejection in Human Immunodeficiency Virus-Positive Kidney Transplant Recipients. Transplantation. 2016;100(4):871-8. DOI 10.1097/TP.0000000000000879.
(36) Stock PG, Barin B, Hatano H, Rogers RL, Roland ME, Lee TH, et al. Reduction of HIV persistence following transplantation in HIV-infected kidney transplant recipients. Am J Transplant. 2014;14(5):1136-41. DOI 10.1111/ajt.12699.
(37) Cohen EA, Mulligan D, Kulkarni S, Tichy EM. De Novo Belatacept in a Human Immunodeficiency Virus-Positive Kidney Transplant Recipient. Am J Transplant. 2016;16(9):2753-7. DOI 10.1111/ajt.13852.
(38) Muthukumar T, Afaneh C, Ding R, Tsapepas D, Lubetzky M, Jacobs S, et al. HIV-infected kidney graft recipients managed with an early corticosteroid withdrawal protocol: clinical outcomes and messenger RNA profiles. Transplantation. 2013;95(5):711-20. DOI 10.1097/TP.0b013e31827ac322.
(39) Werbel WA, Durand CM. Solid Organ Transplantation in HIV-Infected Recipients: History, Progress, and Frontiers. Curr HIV/AIDS Rep. 2019;16(3):191-203. DOI 10.1007/s11904-019-00440-x.
(40) Abbott KC, Swanson SJ, Agodoa LY, Kimmel PL. Human immunodeficiency virus infection and kidney transplantation in the era of highly active antiretroviral therapy and modern immunosuppression. J Am Soc Nephrol. 2004;15(6):1633-9. DOI 10.1097/01.asn.0000127987.19470.3a.
(41) Kumar MS, Sierka DR, Damask AM, Fyfe B, McAlack RF, Heifets M, et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int. 2005;67(4):1622-9. DOI 10.1111/j.1523-1755.2005.00245.x.
(42) Qiu J, Terasaki PI, Waki K, Cai J, Gjertson DW. HIVpositive renal recipients can achieve survival rates similar to those of HIV-negative patients. Transplantation. 2006;81(12):1658-61. DOI 10.1097/01.tp.0000226074.97314.e0.
(43) Roland ME, Barin B, Carlson L, Frassetto LA, Terrault NA, Hirose R, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant. 2008;8(2):355-65. DOI 10.1111/j.1600-6143.2007.02061.x.
(44) Locke JE, Segev DL. Renal Transplantation in HIV-Positive Recipients. Curr Infect Dis Rep. 2010;12(1):71-5. DOI 10.1007/s11908-009-0078-3.
(45) Sawinski D, Forde KA, Eddinger K, Troxel AB, Blumberg E, Tebas P, et al. Superior outcomes in HIV-positive kidney transplant patients compared with HCVinfected or HIV/HCV-coinfected recipients. Kidney Int. 2015;88(2):341-9. DOI 10.1038/ki.2015.74.
(46) Touzot M, Pillebout E, Matignon M, Tricot L, Viard JP, Rondeau E, et al. Renal transplantation in HIVinfected patients: the Paris experience. Am J Transplant. 2010;10(10):2263-9. DOI 10.1111/j.1600-6143.2010.03258.x.
(47) Baisi A, Nava F, Baisi B, Rubbiani E, Guaraldi G, Di Benedetto F, et al. Kidney Transplantation in HIVInfected Recipients: Therapeutic Strategy and Outcomes in Monocentric Experience. Transplant Proc. 2016;48(2):333-6. DOI 10.1016/j.transproceed. 2015.12.038.
(48) Mazuecos A, Fernandez A, Andres A, Gomez E, Zarraga S, Burgos D, et al. HIV infection and renal transplantation. Nephrol Dial Transplant. 2011;26(4):1401-7. DOI 10.1093/ndt/gfq592.
(49) Zheng X, Gong L, Xue W, Zeng S, Xu Y, Zhang Y, et al. Kidney transplant outcomes in HIV-positive patients: a systematic review and meta-analysis. AIDS Res Ther. 2019;16(1):37. DOI 10.1186/s12981-019-0253-z.
(50) Stock PG, Roland ME, Carlson L, Freise CE, Roberts JP, Hirose R, et al. Kidney and liver transplantation in human immunodeficiency virusinfected patients: a pilot safety and efficacy study. Transplantation. 2003;76(2):370-5. DOI 10.1097/01.TP.0000075973.73064.A6.
(51) Husson J, Stafford K, Bromberg J, Haririan A, Sparkes T, Davis C, et al. Association Between Duration of Human Immunodeficiency Virus (HIV)-1 Viral Suppression Prior to Renal Transplantation and Acute Cellular Rejection. Am J Transplant. 2017;17(2):551-6. DOI 10.1111/ajt.13985.
(52) Roland ME, Barin B, Huprikar S, Murphy B, Hanto DW, Blumberg E, et al. Survival in HIV-positive transplant recipients compared with transplant candidates and with HIV-negative controls. AIDS. 2016;30(3):435-44. DOI 10.1097/QAD.0000000000000934.
(53) Ailioaie O, Arzouk N, Valantin MA, Tourret J, Calin RO, Turinici M, et al. Infectious complications in HIVinfected kidney transplant recipients. Int J STD AIDS. 2018;29(4):341-9. DOI 10.1177/0956462417726213.
(54) Miro JM, Aguero F, Duclos-Vallee JC, Mueller NJ, Grossi P, Moreno A, et al. Infections in solid organ transplant HIV-infected patients. Clin Microbiol Infect. 2014;20 Suppl 7:119-30. DOI 10.1111/1469-0691.12754.
(55) Sawinski D, Wong T, Goral S. Current state of kidney transplantation in patients with HIV, hepatitis C, and hepatitis B infection. Clin Transplant. 2020;34(10):e14048. DOI 10.1111/ctr.14048.
(56) Sawinski D. Kidney transplantation for HIV-positive patients. Transplant Rev (Orlando). 2017;31(1):42-6. DOI 10.1016/j.trre.2016.10.003.
(57) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV[internet]. [Consultado 2021 mar 1]. Disponible en. https://cutt.ly/JQ9ZrKS
(58) Crum-Cianflone NF, Wallace MR. Vaccination in HIV-infected adults. AIDS Patient Care STDS. 2014;28(8):397-410. DOI 10.1089/apc.2014.0121.
(59) Nissen NN, Barin B, Stock PG. Malignancy in the HIVinfected patients undergoing liver and kidney transplantation. Curr Opin Oncol. 2012;24(5):517-21. DOI 10.1097/CCO.0b013e328355e0d7.
(60) van Maarseveen EM, Rogers CC, Trofe-Clark J, van Zuilen AD, Mudrikova T. Drug-drug interactions between antiretroviral and immunosuppressive agents in HIVinfected patients after solid organ transplantation: a review. AIDS Patient Care STDS. 2012;26(10):568-81. DOI 10.1089/apc.2012.0169.
(61) Rollins B, Farouk S, DeBoccardo G, Lerner S, Rana M, Huprikar S, et al. Higher rates of rejection in HIV-infected kidney transplant recipients on ritonavir-boosted protease inhibitors: 3-year follow-up study. Clin Transplant. 2019;33(6):e13534. DOI 10.1111/ctr.13534.
(62) Degnan KO, Blumberg EA. Human Immunodeficiency Virus in Kidney Transplantation. Semin Nephrol. 2016;36(5):405-16. DOI 10.1016/j.semnephrol.2016.05.017.
(63) Primeggia J, Timpone JG, Kumar PN. Pharmacologic issues of antiretroviral agents and immunosuppressive regimens in HIV-infected solid organ transplant recipients. Infect Dis Clin North Am. 2013;27(2):473-86. DOI 10.1016/j.idc.2013.02.011.
(64) Sawinski D, Shelton BA, Mehta S, Reed RD, MacLennan PA, Gustafson S, et al. Impact of Protease Inhibitor-Based Anti-Retroviral Therapy on Outcomes for HIV+ Kidney Transplant Recipients. Am J Transplant. 2017;17(12):3114-22. DOI 10.1111/ajt.14419.
(65) Pulzer A, Seybold U, Schonermarck U, Stangl M, Habicht A, Bogner JR, et al. Calcineurin inhibitor dosefinding before kidney transplantation in HIV patients. Transpl Int. 2013;26(3):254-8. DOI 10.1111/tri.12020.
(66) van Maarseveen EM, Crommelin HA, Mudrikova T, van den Broek MP, van Zuilen AD. Pretransplantation pharmacokinetic curves of tacrolimus in HIV-infected patients on ritonavir-containing cART: a pilot study. Transplantation. 2013;95(2):397-402. DOI 10.1097/TP.0b013e3182734651.
(67) Izzedine H, Launay-Vacher V, Baumelou A, Deray G. Antiretroviral and immunosuppressive drug-drug interactions: an update. Kidney Int. 2004;66(2):532-41.
DOI 10.1111/j.1523-1755.2004.00772.x.
(68) Frassetto LA, Browne M, Cheng A, Wolfe AR, Roland ME, Stock PG, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant. 2007;7(12):2816-20. DOI 10.1111/j.1600-6143.2007.02007.x.
(69) Frassetto LA, Tan-Tam C, Stock PG. Renal transplantation in patients with HIV. Nat Rev Nephrol. 2009;5(10):582-9. DOI 10.1038/nrneph.2009.140.
(70) Boyle SM, Malat G, Harhay MN, Lee DH, Pang L, Talluri S, et al. Association of tenofovir disoproxil fumarate with primary allograft survival in HIV-positive kidney transplant recipients. Transpl Infect Dis. 2017;19(4). DOI 10.1111/tid.12727.
(71) Tricot L, Teicher E, Peytavin G, Zucman D, Conti F, Calmus Y, et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant. 2009;9(8):1946-52. DOI 10.1111/j.1600-6143.2009.02684.x.
(72) Azar MM, Malinis MF, Moss J, Formica RN, Villanueva MS. Integrase strand transferase inhibitors: the preferred antiretroviral regimen in HIV-positive renal transplantation. Int J STD AIDS. 2017;28(5):447-58. DOI 10.1177/0956462416651528.
(73) Matignon M, Lelievre JD, Lahiani A, Abbassi K, Desvaux D, Diallo A, et al. Low incidence of acute rejection within 6 months of kidney transplantation in HIV-infected recipients treated with raltegravir: the Agence Nationale de Recherche sur le Sida et les Hepatites Virales (ANRS) 153 TREVE trial. HIV Med. 2019;20(3):202-13. DOI 10.1111/hiv.12700.
(74) Rosa R, Suarez JF, Lorio MA, Morris MI, Abbo LM, Simkins J, et al. Impact of antiretroviral therapy on clinical outcomes in HIV (+) kidney transplant recipients: Review of 58 cases. F1000Res. 2016;5:2893. DOI 10.12688/f1000research.10414.1.
(75) Barcan L, Gadano A, Casetti I, Villamil F, Grupo de Consenso de Transplante de Organos Solidos en Pacientes HIVP. [Organ transplants in HIV infected patients. Update and recommendations]. Medicina (B Aires). 2011;71(1):59-65.
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2021 Universidad de Antioquia
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Los artículos publicados en la revista están disponibles para ser utilizados bajo la licencia Creative Commons, específicamente son de Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional.
Los trabajos enviados deben ser inéditos y suministrados exclusivamente a la Revista; se exige al autor que envía sus contribuciones presentar los formatos: presentación de artículo y responsabilidad de autoría completamente diligenciados.
